FABP1 and metabolic dysfunction-associated steatotic liver disease: Another study (Porras et al., 2017) found that oral QUE (0.05% (wt/wt)) altered GM, which in turn regulated the expression of genes involved in lipid metabolism, including Lxrα, Srebp-1c, Cd36, Fabp1, C/ebpα, and Foxa1. The study also found that QUE reversed impaired intestinal SCFA synthesis and inhibited TLR-4-mediated hepatic inflammation, which ultimately ameliorated NAFLD.